文献速递泌尿生殖与妇科肿瘤放疗

预防性扩大野照射在IIIB期宫颈癌同步放化疗中的疗效评价

Evaluation of the efficacy of prophylactic extended field irradiation in the concomitant chemoradiotherapy treatment of locally advanced cervical cancer, stage IIIB in the 2018 FIGO classification.
PubMed 文献 · Radiat Oncol · 2019-12-16

该回顾性研究纳入2002至2010年北京协和医院133例2018 FIGO IIIB期宫颈癌患者,比较预防性扩大野照射(EFI)与单纯盆腔照射的疗效。结果显示EFI组远处转移显著减少,5年OS、DFS、野外无复发生存(OFRFS)及腹主动脉旁淋巴结无转移生存(PALNMFS)均显著改善,多因素分析显示EFI是DFS、OFRFS和PALNMFS的独立预后因素;EFI组急性并发症更多但无显著更差的急性毒性。结论支持EFI作为IIIB期宫颈癌的有效治疗选择。

要点

  • EFI组远处转移显著少于单纯盆腔照射组。
  • EFI组5年OS、DFS、OFRFS及PALNMFS均显著改善。
  • EFI是DFS、OFRFS和PALNMFS的独立预后因素。

核心结论

  • 预防性EFI在IIIB期宫颈癌同步放化疗中显示预防效应,与5年OS、DFS、OFRFS和PALNMFS的明显改善相关。
  • EFI似乎是FIGO IIIB期宫颈癌患者非常有效的治疗选择。

研究设计与样本

  • 回顾性研究,纳入2002至2010年北京协和医院133例2018 FIGO IIIB期宫颈癌患者。
  • 患者按是否接受EFI或单纯盆腔照射分为两组,在新FIGO分期框架下评估疗效、毒性和预后因素。

主要发现

  • 与单纯盆腔照射相比,预防性EFI组远处转移显著减少。
  • EFI组5年OS、DFS、OFRFS和PALNMFS显著改善。
  • 多因素分析显示EFI是DFS、OFRFS和PALNMFS的独立预后因素。
  • EFI组观察到更多急性并发症,但无显著更差的急性毒性。

临床怎么用

  • 对FIGO IIIB期宫颈癌患者,可考虑在同步放化疗中采用预防性EFI以改善生存并减少远处转移。
  • 采用EFI时需关注急性并发症增加,但无显著更差的急性毒性。

局限性

  • 本研究为回顾性研究,样本来自单一医院2002至2010年病例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The new staging system of cervical cancer issued in 2018 by the International Federation of Gynecology and Obstetrics (FIGO), calls for a new evaluation of the efficacy of prophylactic extended field irradiation (EFI) in the concomitant chemoradiotherapy/brachytherapy treatment of locally advanced cervical cancer patients (stage IIIB). METHODS: We performed a retrospective study consisting of 133 FIGO IIIB cervical cancer patients treated in the Peking Union Medical College Hospital from 2002 to 2010. The patients were distributed in two groups depending whether they were treated with EFI or pelvic only irradiation. The therapeutic efficacy, toxicity and prognostic factors of EFI were evaluated in the frame of the new FIGO staging system. RESULTS: When compared to patients who received pelvic only irradiation, patients who received prophylactic EFI showed significantly less distant metastasis and a significant improvement in their 5 years overall survival (OS), disease free survival (DFS), out of field recurrence free survival (OFRFS) and para-aortic lymph node metastasis free survival (PALNMFS). Multivariate analysis revealed that EFI is an independent prognosis factor for DFS, OFRFS and PALNMFS. Finally, although more acute complications were observed in the EFI group, there is no significantly worst acute toxicity in the EFI group. CONCLUSION: Our retrospective analysis supports the prophylactic effect of EFI in the concomitant chemoradiotherapy treatment of IIIB patients and suggests that this prophylactic effect is associated with a clear improvement in 5-years OS, DFS, OFRFS and PALNMFS. Consequently, EFI appears to be a very valid treatment option for FIGO IIIB cervical cancer patients.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Meng Q, Liu X, Wang W, et al. Evaluation of the efficacy of prophylactic extended field irradiation in the concomitant chemoradiotherapy treatment of locally advanced cervical cancer, stage IIIB in the 2018 FIGO classification. Radiat Oncol. 2019. PMID: 31842919. doi:10.1186/s13014-019-1431-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。